相关实验视频

Updated: May 8, 2026

Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model

Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model

Published on: July 26, 2011

骨髓外宫病毒整合部位2加速阿尔茨海默病的进展

Yuting Cui¹, Xiaomin Zhang¹, Jing Liu¹

¹Clinical Laboratory of Xuanwu Hospital, Capital Medical University, Beijing, People's Republic of China.

|July 12, 2024

概括

在阿尔茨海默氏症中,MEIS2升高.

科学领域:

神经科学是一个神经科学.
分子生物学分子生物学
遗传学遗传学是一个

背景情况:

阿尔茨海默病 (AD) 的特点是粉样蛋白斑块,这是由于失调的粉样蛋白前体蛋白 (APP) 处理造成的.
贝塔位点APP裂变酶1 (BACE1) 启动了粉胺基因路径,使其成为AD病变发生的关键因素.
控制AD中BACE1表达的调控机制在很大程度上仍未被阐明.

研究的目的:

为了研究MEIS homeobox 2 (MEIS2) 在阿尔茨海默病中的作用.
确定MEIS2是否影响BACE1的表达和随后的粉样β生成.
评估MEIS2作为阿尔茨海默病的潜在治疗点.

主要方法:

在AD模型和人类AD患者中量化MEIS2表达.
在MEIS2调制后评估BACE1水平.
在体外研究检查MEIS2与BACE1促进体结合及其对APP处理的影响.

主要成果:

在AD模型和患者中,MEIS2水平显著升高.
降低MEIS2的调节降低了BACE1表达,粉样斑块负载,并改善了AD小鼠的认知功能.
MEIS2直接与BACE1促进体结合,增强其转录并促进粉原性APP裂变.

结论:

通过调节BACE1的表达,MEIS2在阿尔茨海默病中起到关键的转录因子作用.
MEIS2促进了氨基原体路径,有助于AD病理.
准MEIS2为阿尔茨海默病治疗早期干预提供了一个有希望的战略.

关键词:

阿尔茨海默病的疾病阿尔茨海默病的疾病.骨髓状外阴病毒整合部位2 转录途径的转录途径 β-Site粉样蛋白前体蛋白分裂酶 1 1

更多相关视频

Amplification, Next-generation Sequencing, and Genomic DNA Mapping of Retroviral Integration Sites

Amplification, Next-generation Sequencing, and Genomic DNA Mapping of Retroviral Integration Sites

Published on: March 22, 2016

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Published on: December 26, 2016

相关概念视频

Leaky Scanning

Leaky Scanning

During most eukaryotic translation processes, the small 40S ribosome subunit scans an mRNA from its 5' end until it encounters the first start AUG codon. The large 60S ribosomal subunit then joins the smaller one to initiate protein synthesis. The location of the translation initiation is largely determined by the nucleotides near the start codon as there may be multiple translation initiation sites present on the mRNA. Marilyn Kozak discovered that the sequence RCCAUGG (where R stands for...

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Encephalitis ll: Pathophysiology

Encephalitis ll: Pathophysiology

Encephalitis is inflammation of the brain parenchyma caused by direct viral invasion or immune-mediated mechanisms triggered by infections or tumors. Both processes lead to neuronal injury, disrupted neurotransmission, and diverse neurological symptoms, often with overlapping clinical and pathological features.Autoimmune EncephalitisIn autoimmune encephalitis, antibodies target neuronal antigens on cell surfaces, synapses, or within neurons. A key example is anti-NMDAR encephalitis, which can...

Alzheimer Disease l: Introduction

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...

Alzheimer Disease ll: Pathophysiology

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...